Ursodeoxycholic acid
InterventionApproved 19872 papers4 findingsPubChem 31401ChEBI 9907
- Humans1
- Animals1
Mouse lifespan
NIA ITPOutcomes
3Adipogenic differentiation
downin rats1Very low certainty
1 study
Adipogenic differentiation
downin rats1Very low certainty
Ursodeoxycholic acid decreases adipogenic differentiation in rats.
Animalsbone marrow mesenchymal stem cells
Akkermansia muciniphila alleviates osteoporosis by suppressing bone marrow adiposity through the gut microbiota-UDCA-TGR5 axis · Life sciences · 13 Sep 2026
Osteogenesis
upin rats1Very low certainty
1 study
Osteogenesis
upin rats1Very low certainty
Ursodeoxycholic acid increases osteogenesis in rats.
Animalsbone marrow mesenchymal stem cells
Akkermansia muciniphila alleviates osteoporosis by suppressing bone marrow adiposity through the gut microbiota-UDCA-TGR5 axis · Life sciences · 13 Sep 2026
Bone loss
downin rats1Very low certainty
1 study
Bone loss
downin rats1Very low certainty
Ursodeoxycholic acid decreases bone loss in rats.
Animalsin ovariectomized rats
Akkermansia muciniphila alleviates osteoporosis by suppressing bone marrow adiposity through the gut microbiota-UDCA-TGR5 axis · Life sciences · 13 Sep 2026
Associations
1Parkinson's disease
downin humans1RR 0.79Low certainty
1 study
Parkinson's disease
downin humans1RR 0.79Low certainty
Ursodeoxycholic acid lowers the risk of Parkinson's disease in humans (RR 0.79 [95% CI 0.59 to 0.99]).
Humansin adults with hepatobiliary disease
Ursodeoxycholic Acid and Parkinson's Disease Risk: An Emulated Target Trial in UK Electronic Health Records · Movement disorders : official journal of the Movement Disorder Society · 21 Sep 2026
Trials
74Approved
31 Dec 1987 · systemic disease
10 Dec 1997 · Discontinued · Primary Biliary Cholangitis
Repurposing
Phase 4 · Completed · 4 trials
Phase 4 · Active, not recruiting · 1 trial
Phase 4 · Active, not recruiting · 2 trials
Phase 4 · Active, not recruiting · 1 trial
Phase 3 · Completed · 4 trials
Non-alcoholic fatty liver disease
Phase 4 · Completed · 3 trials
All 29Fewer
Phase 4 · Completed · 1 trial
Phase 3 · Completed · 4 trials
Phase 4 · Results posted · 1 trial
Phase 4 · Terminated · 2 trials
Phase 4 · Completed · 2 trials
Phase 2 · Status unknown · 1 trial
Phase 2 · Completed · 1 trial
Phase 2 · Recruiting · 1 trial
Phase 2 · Results posted · 1 trial
Phase 2 · Completed · 1 trial
Phase 2/3 · Completed · 2 trials
Phase 2 · Completed · 2 trials
Phase 2 · Recruiting · 1 trial
Phase 2 · Results posted · 1 trial
Phase 2/3 · Completed · 2 trials
Phase 2 · Completed · 1 trial
Phase 2 · Status unknown · 1 trial
Phase 2/3 · Completed · 1 trial
Phase 1 · Completed · 1 trial
Phase 1/2 · Completed · 1 trial
Phase 1/2 · Status unknown · 1 trial
Phase 1/2 · Status unknown · 1 trial
Phase 1 · Status unknown · 1 trial
In trials
Biliary Liver Cirrhosis
Phase 4 · Completed · 12 trials
Gallstones
Phase 4 · Completed · 4 trials
Autoimmune Hepatitis
Phase 4 · Status unknown · 2 trials
Cholecystolithiasis
Phase 4 · Completed · 2 trials
Diarrhea
Phase 4 · Results posted · 1 trial
Rare Diseases
Phase 3 · Completed · 3 trials
All 10Fewer
Adenomatous Polyposis Coli
Phase 2/3 · Completed · 2 trials
Cholestasis
Phase 2/3 · Completed · 2 trials
Sclerosing Cholangitis
Phase 2/3 · Terminated · 2 trials
Pruritus
Phase 2 · Completed · 1 trial
Stopped
NCT02472509 · Terminated · Gallstones
Study not feasible - very low recruitment rate
NCT00059202 · Terminated · Sclerosing Cholangitis
DSMB reviewed interim analysis and terminated the study due to futility.
Trial sponsors
Company6 trialsPhase 4596 people
Company1 trialPhase 4184 people
Company1 trialPhase 465 people
Company1 trialPhase 3596 people
Company1 trialPhase 2165 people
Company1 trialPhase 298 people
Company1 trialPhase 266 people
Company1 trialPhase 222 people